{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:09:21Z","timestamp":1776204561881,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00432-018-02838-3","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T11:37:54Z","timestamp":1548329874000},"page":"927-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Mistletoe in oncological treatment: a systematic review"],"prefix":"10.1007","volume":"145","author":[{"given":"M.","family":"Freuding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Keinki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kutschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Micke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Buentzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-568X","authenticated-orcid":false,"given":"Jutta","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"2838_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"2838_CR2","first-page":"1058","volume":"49","author":"G Bar-Sela","year":"2013","unstructured":"Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N (2013) Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study European. J Cancer 49:1058\u20131064","journal-title":"J Cancer"},{"key":"2838_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. \n                    https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"2838_CR4","doi-asserted-by":"publisher","first-page":"219402","DOI":"10.1155\/2012\/219402","volume":"2012","author":"A Bussing","year":"2012","unstructured":"Bussing A, Raak C, Ostermann T (2012) Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Altern Med eCAM 2012:219402. \n                    https:\/\/doi.org\/10.1155\/2012\/219402","journal-title":"Evid Based Complement Altern Med eCAM"},{"key":"2838_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1089\/108497803321269304","volume":"18","author":"M Cazacu","year":"2003","unstructured":"Cazacu M et al (2003) The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18:27\u201334","journal-title":"Cancer Biother Radiopharm"},{"key":"2838_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579. \n                    https:\/\/doi.org\/10.1200\/jco.1993.11.3.570","journal-title":"J Clin Oncol"},{"key":"2838_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/oxfordjournals.annonc.a057724","volume":"1","author":"A Coates","year":"1990","unstructured":"Coates A, Glasziou P, McNeil D (1990) On the receiving end\u2014III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1:213\u2013217","journal-title":"Ann Oncol"},{"key":"2838_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00761-004-0825-x","volume":"11","author":"G Deutschinoff","year":"2005","unstructured":"Deutschinoff G, Friedrich C, Dott U, Voigtmann R, Pientka L (2005) Lebensqualit\u00e4t in der Onkologie\u2014Status Quo und Ausblick [Quality of life in oncology\u2014status quo and outlook]. Der Onkologe 11:164\u2013172. \n                    https:\/\/doi.org\/10.1007\/s00761-004-0825-x","journal-title":"Der Onkologe"},{"key":"2838_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejcdt.2015.12.017","volume":"65","author":"RM El-Kolaly","year":"2016","unstructured":"El-Kolaly RM, Abo-Elnasr M, El-Guindy D (2016) Outcome of pleurodesis using different agents in management of malignant pleural effusion Egyptian. J Chest Dis Tuberc 65:435\u2013440","journal-title":"J Chest Dis Tuberc"},{"issue":"2","key":"2838_CR01","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ijc.11386","volume":"107","author":"E Ernst","year":"2003","unstructured":"Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107(2):262\u2013267","journal-title":"Int J Cancer"},{"key":"2838_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3332\/ecancer.2014.424","volume":"8","author":"R Gaafar","year":"2014","unstructured":"Gaafar R, Abdel Rahman ARM, Aboulkasem F, El Bastawisy A (2014) Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin. Ecancermedicalscience 8:424. \n                    https:\/\/doi.org\/10.3332\/ecancer.2014.424","journal-title":"Ecancermedicalscience"},{"key":"2838_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0022-5347(05)64834-3","volume":"168","author":"PJ Goebell","year":"2002","unstructured":"Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168:72\u201375","journal-title":"J Urol"},{"key":"2838_CR12","first-page":"285","volume":"13","author":"R Grossarth-Maticek","year":"2006","unstructured":"Grossarth-Maticek R, Ziegler R (2006a) Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forschende Komplementarmedizin (2006) 13:285\u2013292","journal-title":"Forschende Komplementarmedizin (2006)"},{"key":"2838_CR13","first-page":"485","volume":"11","author":"R Grossarth-Maticek","year":"2006","unstructured":"Grossarth-Maticek R, Ziegler R (2006b) Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 11:485\u2013495","journal-title":"Eur J Med Res"},{"key":"2838_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000285940","volume":"19","author":"R Grossarth-Maticek","year":"2007","unstructured":"Grossarth-Maticek R, Ziegler R (2007a) Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift fur GanzheitsMedizin 19:325\u2013332","journal-title":"Schweizerische Zeitschrift fur GanzheitsMedizin"},{"key":"2838_CR15","first-page":"140","volume":"14","author":"R Grossarth-Maticek","year":"2007","unstructured":"Grossarth-Maticek R, Ziegler R (2007b) Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forschende Komplementarmedizin (2006) 14:140\u2013147","journal-title":"Forschende Komplementarmedizin (2006)"},{"key":"2838_CR16","first-page":"665","volume":"57","author":"R Grossarth-Maticek","year":"2007","unstructured":"Grossarth-Maticek R, Ziegler R (2007c) Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung 57:665\u2013678","journal-title":"Arzneimittelforschung"},{"key":"2838_CR17","first-page":"107","volume":"13","author":"R Grossarth-Maticek","year":"2008","unstructured":"Grossarth-Maticek R, Ziegler R (2008) Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 13:107\u2013120","journal-title":"Eur J Med Res"},{"key":"2838_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0005-7967(94)00091-W","volume":"33","author":"R Grossarth-Maticek","year":"1995","unstructured":"Grossarth-Maticek R, Eysenck HJ, Boyle GJ (1995) Method of test administration as a factor in test validity: the use of a personality questionnaire in the prediction of cancer and coronary heart disease. Behav Res Ther 33:705\u2013710","journal-title":"Behav Res Ther"},{"key":"2838_CR19","first-page":"419","volume":"48","author":"BM Heiny","year":"1997","unstructured":"Heiny BM, Albrecht V (1997) Complementary modes of therapy with mistletoe lectin-1. Medizinische Welt 48:419\u2013423","journal-title":"Medizinische Welt"},{"key":"2838_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003297","author":"MA Horneber","year":"2008","unstructured":"Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in oncology. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD003297","journal-title":"Cochrane Database Syst Rev"},{"key":"2838_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1534735411423920","volume":"11","author":"M Horneber","year":"2012","unstructured":"Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11:187\u2013203. \n                    https:\/\/doi.org\/10.1177\/1534735411423920","journal-title":"Integr Cancer Ther"},{"key":"2838_CR22","first-page":"9","volume":"112","author":"J H\u00fcbner","year":"2015","unstructured":"H\u00fcbner J (2015) Comment on \u2018Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial: several flaws. Deutsches Arzteblatt International 112:9\u20139","journal-title":"Deutsches Arzteblatt International"},{"key":"2838_CR23","first-page":"943","volume":"34","author":"J Huebner","year":"2014","unstructured":"Huebner J et al (2014) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34:943\u2013948","journal-title":"Anticancer Res"},{"key":"2838_CR24","first-page":"191","volume-title":"Evaluation of chemotherapeutic agents","author":"DA Karnofsky","year":"1949","unstructured":"Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia Univ Press, New York, pp\u00a0191\u2013205"},{"key":"2838_CR25","first-page":"3","volume":"12","author":"FA Khan","year":"2005","unstructured":"Khan FA, Akhtar SS, Sheikh MK (2005) Cancer treatment\u2014objectives and quality of life issues Malays. J Med Sci 12:3\u20135","journal-title":"J Med Sci"},{"key":"2838_CR26","first-page":"103","volume":"12","author":"GS Kienle","year":"2007","unstructured":"Kienle GS, Kiene H (2007) Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12:103\u2013119","journal-title":"Eur J Med Res"},{"key":"2838_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/1534735410369673","volume":"9","author":"GS Kienle","year":"2010","unstructured":"Kienle GS, Kiene H (2010) Review article: influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9:142\u2013157","journal-title":"Integr Cancer Ther"},{"key":"2838_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1756-9966-28-79","volume":"28","author":"GS Kienle","year":"2009","unstructured":"Kienle GS, Glockmann A, Schink M, Kiene H (2009) Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 28:79","journal-title":"J Exp Clin Cancer Res"},{"key":"2838_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1472-6882-12-S1-P172","volume":"12","author":"KC Kim","year":"2012","unstructured":"Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R (2012) Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma\u2014a randomized, controlled pilot study. BMC Complement Altern Med 12:172","journal-title":"BMC Complement Altern Med"},{"key":"2838_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","volume":"40","author":"UR Kleeberg","year":"2004","unstructured":"Kleeberg UR et al (2004) Final results of the EORTC 18871\/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness> 3 mm) or regional lymph node metastasis. Eur J Cancer 40:390\u2013402","journal-title":"Eur J Cancer"},{"key":"2838_CR31","first-page":"10581","volume":"2","author":"A-M Lange-Lindberg","year":"2006","unstructured":"Lange-Lindberg A-M, Velasco Garrido M, Busse R (2006) Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess 2:1\u20138","journal-title":"GMS Health Technol Assess"},{"key":"2838_CR32","first-page":"3799","volume":"16","author":"D Lenartz","year":"1996","unstructured":"Lenartz D, Stoffel B, Menzel J, Beuth J (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16:3799\u20133802","journal-title":"Anticancer Res"},{"key":"2838_CR33","first-page":"2073","volume":"20","author":"D Lenartz","year":"2000","unstructured":"Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J (2000) Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20:2073\u20132076","journal-title":"Anticancer Res"},{"key":"2838_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eujim.2009.02.005","volume":"1","author":"A Longhi","year":"2009","unstructured":"Longhi A, Mariani E, Kuehn J (2009) A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. Eur J Integr Med 1:31\u201339","journal-title":"Eur J Integr Med"},{"key":"2838_CR35","doi-asserted-by":"publisher","first-page":"210198","DOI":"10.1155\/2014\/210198","volume":"2014","author":"A Longhi","year":"2014","unstructured":"Longhi A, Reif M, Mariani E, Ferrari S (2014) A randomized study on postrelapse disease-free survival with adjuvant mistletoe versus oral etoposide in osteosarcoma patients. Evid Based Complement Altern Med eCAM 2014:210198. \n                    https:\/\/doi.org\/10.1155\/2014\/210198","journal-title":"Evid Based Complement Altern Med eCAM"},{"key":"2838_CR36","first-page":"217","volume":"16","author":"J Melzer","year":"2009","unstructured":"Melzer J, Iten F, Hostanska K, Saller R (2009) Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forschende Komplementarmedizin (2006) 16:217\u2013226","journal-title":"Forschende Komplementarmedizin (2006)"},{"key":"2838_CR37","first-page":"303","volume":"24","author":"BK Piao","year":"2004","unstructured":"Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24:303\u2013309","journal-title":"Anticancer Res"},{"key":"2838_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1200\/JCO.1984.2.5.472","volume":"2","author":"H Schipper","year":"1984","unstructured":"Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2:472\u2013483. \n                    https:\/\/doi.org\/10.1200\/jco.1984.2.5.472","journal-title":"J Clin Oncol"},{"key":"2838_CR39","first-page":"1293","volume":"24","author":"VF Semiglasov","year":"2004","unstructured":"Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U (2004) The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24:1293\u20131302","journal-title":"Anticancer Res"},{"key":"2838_CR40","first-page":"1519","volume":"26","author":"VF Semiglazov","year":"2006","unstructured":"Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U (2006) Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 26:1519\u20131529","journal-title":"Anticancer Res"},{"key":"2838_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","volume":"34","author":"WO Spitzer","year":"1981","unstructured":"Spitzer WO et al (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585\u2013597","journal-title":"J Chronic Dis"},{"key":"2838_CR42","first-page":"23","volume":"37","author":"MK Steuer-Vogt","year":"2001","unstructured":"Steuer-Vogt MK et al (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial European. J Cancer 37:23\u201331","journal-title":"J Cancer"},{"key":"2838_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00106-005-1318-y","volume":"54","author":"MK Steuer-Vogt","year":"2006","unstructured":"Steuer-Vogt MK, Bonkowsky V, Scholz M, Fauser C, Licht K, Ambrosch P (2006) Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients. Hno 54:277\u2013286","journal-title":"Hno"},{"key":"2838_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12906-016-1326-3","volume":"16","author":"T Stub","year":"2016","unstructured":"Stub T, Quandt SA, Arcury TA, Sandberg JC, Kristoffersen AE, Musial F, Salamonsen A (2016) Perception of risk and communication among conventional and complementary health care providers involving cancer patients\u2019 use of complementary therapies: a literature review. BMC Complement Altern Med 16:353. \n                    https:\/\/doi.org\/10.1186\/s12906-016-1326-3","journal-title":"BMC Complement Altern Med"},{"key":"2838_CR45","first-page":"35","volume":"3","author":"W Troger","year":"2009","unstructured":"Troger W, Jezdic S, Zdrale Z, Tisma N, Hamre HJ, Matijasevic M (2009) Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone Breast cancer. Basic Clin Res 3:35\u201345","journal-title":"Basic Clin Res"},{"key":"2838_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4137\/BCBCR.S10558","volume":"6","author":"W Troger","year":"2012","unstructured":"Troger W, Zdrale Z, Stankovic N, Matijasevic M (2012) Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer Basic Clin Res 6:173\u2013180. \n                    https:\/\/doi.org\/10.4137\/BCBCR.S10558","journal-title":"Breast Cancer Basic Clin Res"},{"key":"2838_CR47","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1016\/j.ejca.2013.06.043","volume":"49","author":"W Troger","year":"2013","unstructured":"Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M (2013) Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 49:3788\u20133797","journal-title":"Eur J Cancer"},{"key":"2838_CR48","first-page":"493","volume":"111","author":"W Troger","year":"2014","unstructured":"Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M (2014a) Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Deutsches Arzteblatt international 111:493\u2013502 (433 p following 502)","journal-title":"Deutsches Arzteblatt international"},{"key":"2838_CR49","doi-asserted-by":"publisher","first-page":"430518","DOI":"10.1155\/2014\/430518","volume":"2014","author":"W Troger","year":"2014","unstructured":"Troger W, Zdrale Z, Tisma N, Matijasevic M (2014b) Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial. Evid Based Complement Altern Med eCAM 2014:430518. \n                    https:\/\/doi.org\/10.1155\/2014\/430518","journal-title":"Evid Based Complement Altern Med eCAM"},{"key":"2838_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1055\/s-0042-113505","volume":"48","author":"W Troger","year":"2016","unstructured":"Troger W, Zdrale Z, Stankovic N (2016) Five-Year follow-up of patients with early stage breast cancer after a randomized study with Viscum album (L.) extract. Deutsche Zeitschrift fur Onkologie 48:105\u2013110","journal-title":"Deutsche Zeitschrift fur Onkologie"},{"key":"2838_CR51","first-page":"354","volume":"17","author":"WHO","year":"1996","unstructured":"WHO (1996) What quality of life? The WHOQOL Group. World Health Organization Quality of Life. Assessment World Health Forum 17:354\u2013356","journal-title":"Assessment World Health Forum"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-02838-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-02838-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-02838-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:11:22Z","timestamp":1579720282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-02838-3"}},"subtitle":["Part\u00a02: quality of life and toxicity of cancer treatment"],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-02838-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}